Cost and Augtyro: Financial Assistance Options, Savings, More

When a doctor prescribes a targeted cancer medicine, the first question is usually medical: “Will this help?” The second question often arrives about two seconds later, wearing steel-toed boots: “How much is this going to cost?” Augtyro, also known by its generic name repotrectinib, is an oral prescription cancer treatment used for certain ROS1-positive non-small cell lung cancers and NTRK gene fusion-positive solid tumors. It is a high-cost specialty medication, which means the sticker price can look like it wandered in from a luxury car showroom.

The good news is that the amount a patient actually pays for Augtyro may be very different from the list price. Insurance coverage, prior authorization, manufacturer co-pay support, Medicare Part D rules, Medicaid policies, independent foundations, and specialty pharmacy coordination can all change the final out-of-pocket cost. The less good news is that this process can feel like solving a crossword puzzle while someone keeps changing the clues. This guide breaks it down in plain English.

What Is Augtyro?

Augtyro is the brand name for repotrectinib, a kinase inhibitor designed to target cancer cells driven by certain gene changes. In the United States, it is approved for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. It is also approved for adults and children 12 years and older with solid tumors that have an NTRK gene fusion, are locally advanced or metastatic, or would require surgery likely to cause severe complications, and have progressed after treatment or have no satisfactory alternative therapy.

In everyday language, Augtyro is not a general chemotherapy drug used for every cancer. It is a precision medicine. Doctors usually consider it after testing confirms that a tumor has a specific genetic driver, such as ROS1 or NTRK. That testing matters because targeted therapies are like keys: impressive when they fit the lock, not very useful when they do not.

How Much Does Augtyro Cost?

The official list price for Augtyro has been reported by Bristol Myers Squibb as $30,740 for a 30-day supply when taken as 160 mg twice daily. That price is the wholesale acquisition cost, not necessarily what a patient pays at the pharmacy. Most people with prescription drug coverage pay less than the list price, although “less” can range from very manageable to “please hold while I sit down.”

Retail price estimates from drug pricing resources also commonly place Augtyro in the tens of thousands of dollars per month without insurance or assistance. Because specialty drug prices can change, and because pharmacies, wholesalers, coupons, insurance contracts, and dispensing fees may differ, patients should treat any online price as an estimate rather than a final bill.

Why the Price Is So High

Augtyro is a brand-name specialty oncology medication with no widely available generic version. Brand-name drugs often cost more because manufacturers must fund research, clinical trials, regulatory review, manufacturing, safety monitoring, and distribution. Specialty oncology drugs also tend to serve smaller patient populations, require careful handling, and may be dispensed through specialty pharmacies rather than ordinary neighborhood drugstores.

This does not make the bill less intimidating. It just explains why the number is so large that it seems to need its own ZIP code.

Factors That Affect Your Augtyro Cost

Your actual cost for Augtyro depends on several moving parts. The most important factor is your insurance type. Commercial insurance, Medicare, Medicaid, TRICARE, and no-insurance situations are handled differently. Your plan’s formulary, deductible, co-insurance percentage, out-of-pocket maximum, prior authorization rules, and specialty pharmacy network can all matter.

Dosage may also affect cost. Augtyro is commonly started at 160 mg once daily for the first 14 days and then increased to 160 mg twice daily if tolerated. Your doctor may reduce, pause, or stop treatment because of side effects. Changes in dosing can affect the amount dispensed, but patients should never adjust the dose on their own to save money. That is a dangerous budget hack, not a treatment plan.

Commercial Insurance and Augtyro Savings

Patients with commercial or private insurance may have the strongest manufacturer savings option. The BMS Access Support Co-Pay Assistance Program may allow eligible commercially insured patients prescribed Augtyro to pay as little as $0 per one-month supply, subject to a maximum benefit and program rules. BMS pricing information has listed a maximum benefit of $15,000 per calendar year for eligible commercially insured patients.

This type of co-pay program is designed to help with deductibles, co-pays, or co-insurance. It does not mean every patient automatically qualifies, and it does not guarantee that the entire cost disappears. Eligibility rules, annual limits, state laws, and insurance restrictions can apply. Still, for a patient with private insurance facing a large oncology co-pay, this is one of the first doors worth knocking on.

What to Ask Your Insurance Plan

Before starting Augtyro, ask your insurer whether the medication is covered under the pharmacy benefit, whether prior authorization is required, whether Augtyro must be filled through a specific specialty pharmacy, and what your expected out-of-pocket cost will be. Also ask whether any co-pay assistance will count toward your deductible or out-of-pocket maximum. Some plans use accumulator or maximizer programs, which can change how manufacturer assistance is applied.

A good phrase to use is: “Can you give me the estimated patient responsibility for Augtyro after approval, and can you explain whether manufacturer co-pay assistance will apply to my deductible?” It is not poetry, but it gets results.

BMS Access Support: What It Can Do

BMS Access Support is the manufacturer’s access and reimbursement support program. It can help patients and healthcare offices understand coverage, conduct benefit investigations, support prior authorization steps, assist with appeals information, and explain financial support options. The program also provides information about co-pay assistance for eligible commercially insured patients.

For Augtyro, BMS Access Support can be especially useful because the medication usually goes through specialty pharmacy channels. A benefits investigation may identify whether the drug is covered, where it must be filled, and what paperwork the oncology office needs to submit. For many patients, this support can turn a confusing process into a checklist.

Prior Authorization and Appeals

Many insurance plans require prior authorization before approving Augtyro. That means the insurer wants evidence that the medication is medically necessary. The oncology team may need to send test results showing ROS1 positivity or NTRK gene fusion, diagnosis details, treatment history, and prescribing information.

If coverage is denied, do not assume the answer is final. Denials can happen because of missing documents, coding issues, formulary rules, or step-therapy requirements. Your doctor’s office may file an appeal, provide additional medical records, or request a peer-to-peer review. BMS Access Support may provide information that helps the office navigate these steps, although the healthcare provider remains responsible for accurate documentation.

Medicare and Augtyro Costs

For people with Medicare, Augtyro costs depend on the Medicare drug plan, the plan’s formulary, coverage phase, income level, and whether the prescription is covered under Part D or a Medicare Advantage plan with drug coverage. Manufacturer co-pay cards generally cannot be used with Medicare, Medicaid, TRICARE, or other government healthcare programs.

However, Medicare Part D has become more protective for people taking expensive medications. In 2026, official Medicare materials state that yearly out-of-pocket costs for covered Part D drugs are capped at $2,100. Once a patient reaches that cap, they should not owe additional copayments or coinsurance for covered Part D drugs for the rest of the calendar year. This can be a major relief for patients on high-cost oral cancer medications.

Medicare beneficiaries may also consider the Medicare Prescription Payment Plan, which allows eligible people to spread out-of-pocket prescription costs into monthly payments over the plan year instead of paying a large amount all at once at the pharmacy. This does not lower the total cost, but it may help with cash flow. Think of it as turning a financial boulder into smaller, less dramatic rocks.

Extra Help and Medicare Counseling

Some Medicare patients qualify for Extra Help, a federal program that lowers prescription drug costs for people with limited income and resources. State Health Insurance Assistance Programs, often called SHIP programs, can also help Medicare beneficiaries compare plans, understand formularies, and prepare for open enrollment.

Because Augtyro is expensive, Medicare patients should review their plan each year. A plan that worked last year may change its formulary, pharmacy network, deductible, or utilization rules. Open enrollment is not exactly a party, but for high-cost medications, it can be financially important.

Medicaid, TRICARE, and Other Government Insurance

Patients with Medicaid or other government insurance are not eligible for manufacturer-sponsored co-pay assistance from Bristol Myers Squibb. Medicaid coverage and cost-sharing vary by state, so patients should contact their state Medicaid program or managed care plan to understand whether Augtyro is covered and what prior authorization rules apply.

TRICARE and other government programs may also have their own coverage rules. The key is to ask early. Do not wait until the specialty pharmacy calls with a cost that makes your phone feel heavier.

Uninsured or Underinsured Patients

If you do not have prescription drug coverage, the list price of Augtyro may apply unless discounts or assistance programs are available. BMS Access Support may provide information about independent charitable foundations or other support resources. The Bristol Myers Squibb Patient Assistance Foundation is an independent charitable organization that may help eligible patients receive certain BMS medications at no cost, depending on program criteria.

Eligibility often involves U.S. residency, a valid prescription, treatment by a licensed U.S. healthcare professional, financial hardship, and insurance status. These programs can open and close, funding can change, and acceptance is not guaranteed. Still, uninsured or underinsured patients should not assume there is no help. Ask the oncology social worker, financial navigator, specialty pharmacy, and manufacturer access program to check every available option.

Independent Foundations and Cancer Support Organizations

Independent nonprofits can sometimes help with co-pays, premiums, transportation, lodging, and other treatment-related expenses. Examples of cancer-related support organizations include CancerCare, HealthWell Foundation, LUNGevity Foundation, Patient Advocate Foundation, and disease-specific or local community funds. These organizations are separate from the drug manufacturer and have their own eligibility rules.

Some foundations offer disease-based funds rather than drug-specific funds. That means a patient with lung cancer may apply under a lung cancer or oncology category if funding is open. The frustrating part is that funds can close quickly when demand is high. The practical move is to check repeatedly, sign up for alerts when available, and ask a financial navigator to help monitor openings.

Specialty Pharmacies and Shipping

Augtyro is typically handled by specialty pharmacies, not ordinary retail pharmacies. Specialty pharmacies manage expensive or complex medications, coordinate insurance approvals, arrange shipping, collect co-pays, and may offer refill reminders or adherence support. Before Augtyro ships, the pharmacy generally needs insurance approval, patient contact information, delivery confirmation, and payment arrangements.

Patients should answer calls from unfamiliar pharmacy numbers during the approval process. Yes, spam calls have trained us all to distrust the phone, but specialty pharmacies often need to verify details before sending medication. Missing a call can delay shipment.

Practical Ways to Reduce Augtyro Costs

1. Start the Benefits Investigation Immediately

Ask your oncology team to begin a benefits investigation as soon as Augtyro is prescribed. This can reveal coverage rules, required forms, specialty pharmacy restrictions, and estimated out-of-pocket costs before the first fill.

2. Ask About the BMS Co-Pay Program

If you have commercial insurance, ask whether you qualify for BMS co-pay assistance. Even if your insurance already covers Augtyro, co-insurance on a drug with a five-figure monthly price can still be painful. Co-pay support may significantly reduce that burden.

3. Check Medicare Part D Details

Medicare patients should confirm whether Augtyro is covered, what tier it is on, whether prior authorization is needed, and how quickly they may reach the annual out-of-pocket cap. They should also ask whether the Medicare Prescription Payment Plan would make monthly costs easier to manage.

4. Work With an Oncology Financial Navigator

Many cancer centers have financial navigators, social workers, or reimbursement specialists. These professionals know the difference between a co-pay card, a foundation grant, a prior authorization, and an appeal. In other words, they speak fluent insurance, which is a dialect no one should have to learn during cancer treatment.

5. Keep Records Like a Tiny Accountant

Save approval letters, denial letters, pharmacy invoices, grant award notices, co-pay card information, and shipment receipts. If there is a billing dispute, these documents are your receipts, your timeline, and your sanity-preserving paper trail.

Safety Costs: Do Not Ignore Monitoring

Medication cost is not the only financial consideration. Augtyro may require monitoring and follow-up appointments. Serious possible side effects include central nervous system effects, lung problems such as pneumonitis, liver problems, muscle problems with creatine phosphokinase elevation, increased uric acid levels, bone fractures, and embryo-fetal toxicity. Your healthcare provider may order blood tests before and during treatment, especially early in therapy.

Patients should ask whether labs, scans, follow-up visits, and supportive medications are covered by insurance. These costs may be billed separately from the medication itself. If a patient focuses only on the prescription co-pay, surprise medical bills can sneak in through the side door wearing tap shoes.

Questions to Ask Before Starting Augtyro

• Is Augtyro covered by my insurance plan?
• Does my plan require prior authorization or an appeal?
• Which specialty pharmacy must fill the prescription?
• What will my first fill cost, and what will refills cost?
• Do I qualify for the BMS Access Support Co-Pay Assistance Program?
• If I have Medicare, how will the 2026 Part D out-of-pocket cap affect me?
• Could I qualify for Extra Help, Medicaid, or an independent foundation grant?
• Who at the clinic can help with financial navigation?

Common Mistakes to Avoid

One common mistake is assuming that “covered” means “affordable.” A plan may cover Augtyro but still require a large co-insurance payment. Another mistake is waiting until the pharmacy is ready to ship before asking about assistance. By then, everyone is in a hurry, and insurance paperwork does not become more charming under pressure.

Patients should also avoid using random discount cards without checking whether the purchase will count toward their insurance deductible or Medicare out-of-pocket spending. Paying outside insurance may look cheaper for one fill, but it can sometimes interfere with reaching plan limits. Always ask the pharmacist or insurance plan to compare options before choosing.

Experiences Related to Augtyro Cost and Financial Assistance

Imagine a patient named Linda, a retired teacher with Medicare Part D. Her oncologist prescribes Augtyro after biomarker testing confirms ROS1-positive non-small cell lung cancer. Linda’s first reaction is hope. Her second reaction is sticker shock. The specialty pharmacy explains that Augtyro is covered, but she will owe a large amount early in the year. Her clinic’s financial navigator helps her understand the Medicare Part D cap and the Medicare Prescription Payment Plan. Instead of trying to pay the whole early-year amount at once, Linda spreads her costs over monthly payments. The total is still serious, but the payment schedule becomes less chaotic. Linda says the process felt like “doing taxes in a thunderstorm,” but having one person at the cancer center coordinate calls made it manageable.

Now consider Marcus, who has commercial insurance through his employer. His plan approves Augtyro but assigns a high co-insurance amount. The specialty pharmacy tells him the monthly out-of-pocket cost before assistance. Marcus nearly drops his coffee, which would have been tragic because it was the good coffee. His oncology office connects him with BMS Access Support, and he applies for the manufacturer co-pay program. After approval, his monthly responsibility is dramatically reduced, subject to the program’s annual maximum. Marcus learns to track how much of the annual co-pay benefit has been used so he is not surprised later in the year.

A third patient, Rosa, has no prescription drug coverage. Her clinic immediately contacts a financial navigator, who checks BMS Patient Assistance Foundation resources, independent charitable foundations, local cancer support groups, and state coverage options. Rosa’s application requires income documentation, a prescription, diagnosis details, and signatures from both her and her prescriber. The paperwork takes effort, but it creates a path forward. Her lesson is simple: uninsured does not always mean unsupported, but help rarely appears automatically. Someone has to ask, apply, fax, upload, call, and follow up.

Caregivers often become the unofficial project managers of medication access. A spouse may track shipment dates, a daughter may sit on hold with insurance, or a friend may drive to appointments while the patient rests. The best experiences usually involve a shared spreadsheet or folder with insurance cards, medication names, phone numbers, application dates, approval letters, and refill schedules. It may not be glamorous, but neither is losing a grant approval letter under a stack of mail.

Patients also describe the emotional side of cost conversations. Some feel embarrassed to ask for financial help. They should not. Specialty cancer medications are expensive by design, and assistance programs exist because the gap between list price and household budgets is real. Asking about cost is not complaining. It is part of responsible treatment planning.

The most useful real-world habit is to ask the same question at every step: “What happens next, and who owns that step?” If the doctor writes the prescription, who submits prior authorization? If the plan denies it, who files the appeal? If the specialty pharmacy needs consent, who calls the patient? If the co-pay is high, who checks assistance? This simple question prevents the prescription from getting stuck in the mysterious fog between clinic, insurer, pharmacy, and patient.

Conclusion

Augtyro can be an important targeted treatment option for eligible patients with ROS1-positive non-small cell lung cancer or NTRK gene fusion-positive solid tumors, but its cost can be substantial. The list price is high, and uninsured cash costs may be overwhelming. Fortunately, many patients do not pay list price. Commercially insured patients may qualify for BMS co-pay assistance. Medicare patients may benefit from the 2026 Part D out-of-pocket cap and payment-smoothing options. Medicaid patients, uninsured patients, and underinsured patients may need help through state programs, independent foundations, or patient assistance resources.

The smartest strategy is early coordination. Ask your oncology team, financial navigator, insurer, specialty pharmacy, and BMS Access Support about coverage and savings before the first fill. In cancer care, paperwork should never be the loudest voice in the room, but handling it early can make the whole treatment journey less stressful.

Note: This article is for educational publishing purposes only and should not replace medical, insurance, legal, or financial advice. Patients should confirm current pricing, eligibility, coverage, and assistance details with their healthcare team, insurer, specialty pharmacy, Medicare plan, Medicaid office, or BMS Access Support before making treatment decisions.